Trial · NCT07888387
Temporal Interference Stimulation in Major Depressive Disorder: A Pilot Feasibility Study
NCT07888387, Not applicable, Completed, Ruijin Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Temporal Interference Stimulation in Major Depressive Disorder: A Pilot Feasibility Study. Trials, record NCT07888387. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07888387
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Temporal Interference Stimulation in Major Depressive Disorder: A Pilot Feasibility Study
- NCT number
- NCT07888387
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 15 participants, actual
- Lead sponsor
- Ruijin Hospital
- Conditions
- Major Depressive Disorder (MDD)
- Interventions
- Temporal Interference Stimulation, Temporal Interference Stimulation, Temporal Interference Stimulation, Temporal Interference Stimulation, Temporal Interference Stimulation
- First posted
- 2026-10-22
- Last updated
- 2026-10-22
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants Who Completed All Five Stimulation Sessions | Up to 5 weeks | Feasibility, defined as the number of enrolled participants who completed all five weekly 20-minute stimulation sessions. Reported descriptively; no formal hypothesis test. |
| Primary | Number of Participants With Adverse Events | Up to 5 weeks | Tolerability, defined as the number of participants experiencing at least one adverse event during or after any of the five stimulation sessions, summarized by severity (mild, moderate, severe). Reported descriptively; no formal hypothesis test. |
| Primary | Participant-Reported Discomfort During Stimulation | Immediately after each of the five weekly sessions (Weeks 1-5) | Discomfort during each 20-minute session, record the number of participants reporting any discomfort. Reported descriptively; no formal hypothesis test. |
| Primary | Change in resting-state functional connectivity | Immediately before and after each stimulation session | Seed-based resting-state functional connectivity computed from fMRI acquired immediately before and after each session. For each target, FC is the Fisher z-transformed temporal correlation between the seed time series and other voxels. Outcome is the pre-to-post change (post minus pre) under active stimulation versus sham, at group level. |
| Secondary | Change in depressive symptoms (HAMD) | Baseline (before the first session), Weeks 2, 3, 4,5,7 | Depressive symptom severity measured by the 17-item Hamilton Depression Rating Scale (HAMD-17). Total score ranges from 0 to 52; higher scores indicate more severe depressive symptoms (worse outcome). Outcome is the change in total score from baseline, analyzed as a secondary, exploratory measure. Study not powered for target-specific or antidepressant effects. |
| Secondary | Change in anxiety symptoms (HAMA) | Baseline, Weeks 2, 3, 4, 5, and 7 | Anxiety symptom severity measured by the 14-item Hamilton Anxiety Rating Scale (HAMA). Total score ranges from 0 to 56; higher scores indicate more severe anxiety symptoms (worse outcome). Outcome is the change in total score from baseline, analyzed as a secondary, exploratory measure. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07888387
GET https://conductscience.org/api/trials/v1/NCT07888387/registered